These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 38698841)

  • 1. Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease.
    Wei Z; Wang J
    Front Immunol; 2024; 15():1375654. PubMed ID: 38698841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of Shared Gene Signatures and Molecular Mechanisms Between Periodontitis and Nonalcoholic Fatty Liver Disease.
    Xu W; Zhang Z; Yao L; Xue B; Xi H; Wang X; Sun S
    Front Genet; 2022; 13():939751. PubMed ID: 35836570
    [No Abstract]   [Full Text] [Related]  

  • 3. Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study.
    Tuo L; Yan LT; Liu Y; Yang XX
    Front Endocrinol (Lausanne); 2024; 15():1315046. PubMed ID: 38681765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Inflammatory Factors in Mediating the Effect of Lipids on Nonalcoholic Fatty Liver Disease: A Two-Step, Multivariable Mendelian Randomization Study.
    Chen J; Zhou H; Jin H; Liu K
    Nutrients; 2022 Oct; 14(20):. PubMed ID: 36297117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota does not play a mediating role in the causal association between inflammatory bowel disease and several its associated extraintestinal manifestations: a Mendelian randomization study.
    Lu W; Cen J; Dai Q; Tao H; Peng L
    Front Immunol; 2023; 14():1296889. PubMed ID: 38288127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome-wide Mendelian randomization identifies potential therapeutic targets for nonalcoholic fatty liver diseases.
    Li J; Ma X; Yin C
    Sci Rep; 2024 May; 14(1):11814. PubMed ID: 38782984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nonalcoholic fatty liver disease and risk of erectile dysfunction: A bidirectional two-sample mendelian randomization study].
    Cheng P; Wang YW; Shen YJ
    Zhonghua Nan Ke Xue; 2023 Aug; 29(8):705-710. PubMed ID: 38619516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics.
    Liu J; Wu P; Lai S; Wang J; Wang J; Zhang Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16885-16904. PubMed ID: 37740761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health condition and socioeconomic status mediate the causal effect of reproductive traits on nonalcoholic fatty liver disease: evidence from Mendelian randomization study.
    Wang Q; Wang L; Hao R; Zhang L; Wang W; Xia L
    Front Endocrinol (Lausanne); 2024; 15():1419964. PubMed ID: 39280015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Causal Relationships Between Periodontitis and Non-alcoholic Fatty Liver Disease: A Two-Sample Bidirectional Mendelian Randomisation Study.
    Cheng X; Chen J; Liu S; Bu S
    Oral Health Prev Dent; 2024 May; 22():189-202. PubMed ID: 38803319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the causal effect of circulating proteome on the risk of inflammatory bowel disease-related traits using Mendelian randomization.
    Li B; Hu P; Liang H; Zhao X; Zhang A; Xu Y; Zhang B; Zhang J
    Front Immunol; 2024; 15():1434369. PubMed ID: 39144148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis.
    Fan JC; Lu Y; Gan JH; Lu H
    Int J Colorectal Dis; 2024 Oct; 39(1):165. PubMed ID: 39414629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between inflammatory bowel disease and frailty: a two-sample Mendelian randomization study.
    Feng J; Chen X; Cai W; Zhou X; Zhang X
    Aging Clin Exp Res; 2024 Feb; 36(1):21. PubMed ID: 38319411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mendelian randomization study for the roles of IL-18 and IL-1 receptor antagonist in the development of inflammatory bowel disease.
    Mi J; Liu Z; Pei S; Wu X; Zhao N; Jiang L; Zhang Z; Bai X
    Int Immunopharmacol; 2022 Sep; 110():109020. PubMed ID: 35843146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study.
    Cui G; Li S; Ye H; Yang Y; Huang Q; Chu Y; Shi Z; Zhang X
    Front Immunol; 2022; 13():956005. PubMed ID: 36159838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and heart failure: A comprehensive bioinformatics and Mendelian randomization analysis.
    Zhang Y; Feng L; Guan X; Zhu Z; He Y; Li X
    ESC Heart Fail; 2024 Dec; 11(6):4185-4200. PubMed ID: 39143741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-sample Mendelian randomization analysis evaluates causal associations between inflammatory bowel disease and osteoporosis.
    Dai Z; Xu W; Ding R; Peng X; Shen X; Song J; Du P; Wang Z; Liu Y
    Front Public Health; 2023; 11():1151837. PubMed ID: 37304119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroesophageal reflux disease and non-alcoholic fatty liver disease: a two-sample Mendelian randomization combined with meta-analysis.
    Leng X; Liao WZ; Zheng FP
    Sci Rep; 2024 Jun; 14(1):12633. PubMed ID: 38824176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causal relationship between nonalcoholic fatty liver disease and different sleep traits: a bidirectional Mendelian randomized study.
    Sun Z; Ji J; Zuo L; Hu Y; Wang K; Xu T; Wang Q; Cheng F
    Front Endocrinol (Lausanne); 2023; 14():1159258. PubMed ID: 37334291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.